Vincerx Pharma, Inc. (VINCU) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Palo Alto, CA, アメリカ.
VINCU を有する IPO日 2020-12-29, 42 名の正社員, に上場 NASDAQ Global Select.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
